about
No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients.Could HBx protein expression affect signal pathway inhibition by gefitinib or selumetinib, a MEK inhibitor, in hepatocellular carcinoma cell lines?Clinicobiochemical prediction of biopsy-proven cases of severe hepatic fibrosis in patients with chronic hepatitis C infectionFibroblast growth factor receptor isotype expression and its association with overall survival in patients with hepatocellular carcinoma.A case of primary hepatic actinomycosis: an enigmatic inflammatory lesion of the liver.Propensity Score Matching Analysis of Changes in Alpha-Fetoprotein Levels after Combined Radiotherapy and Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.Alpha-fetoprotein normalization as a prognostic surrogate in small hepatocellular carcinoma after stereotactic body radiotherapy: a propensity score matching analysis.Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial.Clinical course of chronic hepatitis B patients who were off-treated after lamivudine treatment: analysis of 138 consecutive patientsFocal type of peliosis hepatisRandomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patients.A Nationwide Retrospective Study of Opioid Management Patterns in 2,468 Patients with Spinal Pain in Korea.Novel Preoperative Nomogram for Prediction of Futile Resection in Patients Undergoing Exploration for Potentially Resectable Intrahepatic Cholangiocarcinoma.Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma.Role of 15-hydroxyprostaglandin dehydrogenase down-regulation on the prognosis of hepatocellular carcinoma.Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses.Prognostic nomograms for prediction of recurrence and survival after curative liver resection for hepatocellular carcinoma.Clinical validity of Metroticket calculator in transplant patients undergoing prior chemoembolization for hepatocellular carcinoma.Absence of Benefit of Transcatheter Arterial Chemoembolization (TACE) in Patients with Resectable Solitary Hepatocellular Carcinoma.Prognostic value of hepatocyte nuclear factors 4α and 1α identified by tissue microarray in resectable hepatocellular carcinoma.Clinical characteristics and potential aetiologies of non-B non-C hepatocellular carcinoma in hepatitis B virus endemic area.Subtraction Images of Gadoxetic Acid-Enhanced MRI: Effect on the Diagnostic Performance for Focal Hepatic Lesions in Patients at Risk for Hepatocellular Carcinoma.A Patient-Based Nomogram for Predicting Overall Survival after Radiofrequency Ablation for Hepatocellular Carcinoma.Nomograms for Predicting Outcomes after Chemoembolization in Patients with Nonmetastatic Hepatocellular Carcinoma.Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis.Clinical features and outcomes of patients with hepatocellular carcinoma complicated with bile duct invasion.Validation and reappraisal of the assessment for retreatment with transarterial chemoembolization score for unresectable non-metastatic hepatocellular carcinoma in a hepatitis b virus-endemic region.Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis.Expression of carbonic anhydrase 9 is a novel prognostic marker in resectable hepatocellular carcinoma.Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance.Optimal methods for measuring eligibility for liver transplant in hepatocellular carcinoma patients undergoing transarterial chemoembolization.Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine.Reappraisal of serum alpha-foetoprotein as a surveillance test for hepatocellular carcinoma during entecavir treatment.Assessment of current criteria for primary nonresponse in chronic hepatitis B patients receiving entecavir therapy.Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology.Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis.Prognostic Scoring Models for Patients Undergoing Sorafenib Treatment for Advanced Stage Hepatocellular Carcinoma in Real-Life Practice.Prognostic performance of preoperative gadoxetic acid-enhanced MRI in resectable hepatocellular carcinoma.Safety and efficacy of adjuvant pegylated interferon therapy for metastatic tumor antigen 1-positive hepatocellular carcinoma.Clinical courses of chronic hepatitis B virus infection and inflammatory bowel disease in patients with both diseases.
P50
Q33905607-AFD3C540-CF98-4F4F-9CD2-7BB8752117B4Q34539948-E76F2473-70C3-4C2C-A4DA-C20AB304AC27Q34589232-12671987-34EF-42A9-8714-75053B785EADQ35231830-E5C347D1-4AD7-4D6B-BC59-272A75CB88DFQ35231844-66286052-F31A-452F-AB08-9F4AC5AD88F0Q35739788-23FB5F37-46F9-4317-9A98-6B9BB2C68E28Q35872656-1F406E1A-0B4E-4058-B615-981E0268FD28Q36254363-6503674B-4130-4014-8518-D7FA45A51A0DQ36391991-EDA458EA-2EC0-4BA3-A560-6C47395876AFQ36460270-400E1BBD-331B-4548-A4D5-2F613EB08E88Q36969950-0066C785-7F36-490A-8C46-F2BC052071C8Q37512108-D680C4A6-4C22-45B0-910B-1D84673A5588Q37648609-56B45D90-547C-43F7-A2B5-C4A9BED37F93Q37687559-B4889B0D-9E19-4C88-AF89-E5A1C6BF3135Q37711314-B53CB3DA-D7D0-4DA9-8679-7E5F4D3927B2Q38122306-595A9CF8-2365-4FEE-9D02-7F506C563FA2Q38221934-2D44AB72-A2B2-4B05-B8CE-9F28FC331E3CQ38406220-F75A8AA4-98C6-44BA-81AD-1A0E8B936A7AQ38419592-B7BE759A-8AAF-479E-A769-EB8061930421Q39360576-2EF0429A-82A7-4029-B87D-E3C331875B33Q39970001-EA568994-A71E-4658-B4B9-0B30D07F6148Q40161944-53B6060E-E069-412E-8350-95FF45A648E7Q40350309-DA1DF0E0-208B-4BBA-8232-26983F493881Q40833378-BFBD47CF-0B36-43FB-9B6D-C818C261EE9DQ40870495-DFF029C2-7E71-484A-BB4A-B00B171D1BD0Q40961796-02ACF01D-8E4E-4547-94A9-44F8A668D6A7Q40989844-916B78E3-0298-4C7C-9499-585DABA5F1AEQ41542487-F83C403C-32CF-4421-9612-8BB47E35C5F7Q41596438-9D310294-3E77-45A2-80AB-FC1488184990Q41637137-4B5E5C91-08B1-4A3A-9829-E34C7710C6EFQ41662337-0B86AEA1-0225-4314-9D48-A92A817F549EQ42234528-4E60E57D-0E45-4B20-BE18-C77C021DC00FQ42234864-83168576-492E-4026-AD88-A6DE9B66C031Q42259021-3B1FF5FD-F8A0-4D17-B9E5-CEFDF1BEE820Q43159400-43798723-57DD-4558-B4DE-38F2B37ED2F6Q43223823-67640B4A-CD33-471D-8D94-92C2104CC405Q43923614-EA2F9253-24C6-4614-8764-00167112ED64Q44199365-F57BDABE-8C1E-4A2C-85D6-2785F2DDE520Q44365724-2ED7A0A6-95ED-4DD8-8C45-1EDAC6A09FA2Q45359644-563318A7-005C-4593-BE89-D26EC1CB7AFF
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Ju Hyun Shim
@en
Ju Hyun Shim
@nl
type
label
Ju Hyun Shim
@en
Ju Hyun Shim
@nl
prefLabel
Ju Hyun Shim
@en
Ju Hyun Shim
@nl
P31
P496
0000-0002-7336-1371